Artificial intelligence (AI)-based systems have been shown to reliably recognize cardiovascular disease risk 1 and diagnose conditions such as diabetic retinopathy 2,3 and melanoma 4 from medical images. These advances in image-based medical diagnosis have been widely publicized in the media and similar tools have been approved by the US Food and Drug Administration (FDA). In April of 2018, the FDA approved the first AI device to provide screening decision for a disease (ie, diabetic retinopathy) without assisted interpretation by a clinician. 5 Kanagasingam et al 6 evaluated a similar approach-a convolutional neural network algorithm, a deep learning method-for identifying diabetic retinopathy from medical images in a primary care setting in Midland, Western Australia.
patients needing to be reviewed by an ophthalmologist was less than 10%. These findings demonstrate the potential for these systems to support efficient and improved care, while also highlighting the need for rigorous evaluation in clinical settings.
Most deep learning algorithms require large data sets for training, usually consisting of thousands or millions of images. Medical data sets of this magnitude are typically expensive to produce and annotate. Individuals developing AI diagnostic tools might therefore rely on whatever data are available to produce initial results. However, certain deficiencies might not be evident until an AI diagnostic tool is evaluated in a clinical setting because data sets used for training have been carefully curated to remove imperfect data samples. For example, a system trained only on high- Although multiple studies have demonstrated that AI can perform on par with clinical experts in disease diagnosis, most of these tools have not been evaluated in controlled clinical studies to assess their effect on health care decisions and patient outcomes. While AI tools have the potential
